UNITED STATES

                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                    Form 8-K

                                 Current Report

                       Pursuant to Section 13 or 15(d) of

                           The Securities Act of 1934

Date of Report (Date of earliest event reported)   July 13, 2000 (July 12, 2000)



                             MYLAN LABORATORIES INC.

           (Exact name of registrant as specified in its charter)



Pennsylvania                   1-9114                               25-1211621
  (State or other            (Commission                      (I.R.S. Employer
  jurisdiction of           File Number)                   Identification No.)
  incorporation)



                               130 Seventh Street

                              1030 Century Building

                                   Pittsburgh, PA                 15222
                (Address of principal executive offices)        (Zip Code)


Registrant's telephone number, including area code            (412) 232-0100







Item 5.  Other Events.

         The Registrant's  News Release dated July 12, 2000,  attached hereto as
Exhibit 99.1, is incorporated herein by reference.

Item 7.  Financial Statements and Exhibits.

         (a)        Financial statements of businesses acquired.

                    None.

(b)      Pro forma financial information.

                    None.

         (c)        Exhibits.

                    99.1      News Release dated July 12, 2000.


                                   SIGNATURES

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                         MYLAN LABORATORIES INC.

                                         By:        /s/ Milan Puskar
                                                    --------------------------
                                                   Milan Puskar, Chairman and
                                                      Chief Executive Officer

Date:        July 13, 2000
             Pittsburgh, Pennsylvania





NEWS RELEASE                                                   Contact:
                                                       Patricia Sunseri
                                                           412-232-0100
For Immediate Release

            Mylan Laboratories Announces Proposed Settlement With FTC

PITTSBURGH,  Pa., July 12, 2000 - Mylan  Laboratories Inc. (NYSE: MYL) announced
today  that it has  reached  a  tentative  settlement  with  the  Federal  Trade
Commission and State  Attorneys  General over lawsuits filed against the company
in December 1998.

Mylan also has  reached a tentative  agreement  to settle  private  class-action
lawsuits  filed  against  the  company on behalf of  consumers  and  third-party
reimbursers  related to the same legal issues addressed in the FTC and Attorneys
General cases.

The company has agreed to pay a total of $135 million in  settlement  plus up to
$12 million in attorney fees.  Final  settlement  documents are being negotiated
with the  FTC,  States'  Attorneys  General  and  lawyers  representing  private
plaintiffs.  These  settlements  also include  three  companies  indemnified  by
Mylan--Cambrex Corporation, Profarmaco S.r.l. and Gyma Laboratories, Inc.

Mylan continues to strongly  dispute all allegations and admits to no wrongdoing
in the  settlements.  The proposed  settlement with the FTC is subject to review
and  approval of the FTC  commissioners.  Court  approval  will also be required
before the settlements become final.

"This is the first time in Mylan's  39-year  history that any government  agency
has accused us of  improper  conduct,"  said Milan  Puskar,  Chairman  and Chief
Executive  Officer  of Mylan  Laboratories.  "We  continue  to  believe we acted
properly.  However,  the Board and I view  these  settlements  to be in the best
interest of our company's  shareholders,  customers and employees.  By putting a
significant  portion of this case behind us, we can now look forward to devoting
our full resources to the business of this company."

                                     (more)

 Lawsuits  not included in the  settlements  principally  involve  institutional
purchasers such as wholesalers.  Mylan intends to vigorously defend these cases.
The company  believes these cases are  inappropriate  as class  actions,  do not
properly state a claim or are covered by the settlements.

Mylan is a fully integrated  pharmaceutical  company with Corporate headquarters
in  Pittsburgh.  In addition to generic  products,  the company  also  develops,
produces,  markets and  distributes a growing number of innovative,  proprietary
drugs.  More  information  about  the  company  is  available  at its web  site,
www.mylan.com.

                                       ###